Background: The current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID-19.
Aim: To summarise the scale of the COVID-19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID-19 management options and drug interactions in the IBD population.
Methods: A literature review on IBD, SARS-CoV-2 and COVID-19 was undertaken and relevant literature was summarised and critically examined.
Results: IBD patients do not appear to be more susceptible to SARS-CoV-2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID-19. IBD medication adherence should be encouraged to prevent disease flare but where possible high-dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co-morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID-19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID-19 are being considered, potential drug interactions should be checked.
Conclusion: IBD patient management presents a challenge in the current COVID-19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.
© 2020 John Wiley & Sons Ltd.
The Greek Response to COVID-19: A True Success Story from an IBD Perspective.Inflamm Bowel Dis. 2020 Jun 1:izaa143. doi: 10.1093/ibd/izaa143. Online ahead of print. Inflamm Bowel Dis. 2020. PMID: 32476001
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).Cureus. 2020 Apr 6;12(4):e7560. doi: 10.7759/cureus.7560. Cureus. 2020. PMID: 32269893 Free PMC article. Review.
[Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?].Encephale. 2020 Apr 22:S0013-7006(20)30076-2. doi: 10.1016/j.encep.2020.04.008. Online ahead of print. Encephale. 2020. PMID: 32370984 Free PMC article. French.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Apr 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
- World Health Organisation. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. March 16, 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020.
- Chan J-W, To K-W, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21:544-555.
- Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol. 2015;6:169-174.
- Jeong DY, Kim S, Son MJ, et al. Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review. Autoimmun Rev. 2019;18:439-454.